Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:36:59.079Z.
Calculation as of: 2026-10-06T13:36:59.079Z.
Quote observation: 2026-10-06T13:33:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fe223a2c9097866a428bc5ebda2476775355ce68fd4daeb413d6e89482dd9b46
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$897948.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$872428.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$800351.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.03M
Price/OCF Ratio
N/A
TTM Avg
60791.74
3Y Avg
60791.74
5Y Avg
60791.74
Market Cap
$1.14M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.15M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GlucoTrack, Inc. (GCTK) | $901902.00 | N/A | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $897948.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $872428.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $800351.00 | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | N/A | 60791.74 | 60791.74 | 60791.74 |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $685948.00 | 0.01 | 0.16 | 40.30 | 40.30 |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.15M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | 2.88 | 2.62 | 2.62 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
